EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy

Jia Li, Abdulkareem Qasem Moqbel, Yongzhao Wang, Erhu Zhao, Muhammad Usman Ghani, Ping Liang

Biochemical Pharmacology · 2026-04 · 246 · 117724

DOI: 10.1016/j.bcp.2026.117724 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026-04. Verfasst von Jia Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Biological Sciences and Biotechnology, Beijing Forestry University, Haidian, Beijing 100083, China; Faculty of Forestry, The University of…. Hauptthemen laut MEDLINE: Glioblastoma, Tumor Microenvironment, Immunotherapy, Brain Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: Chongqing Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is one of the most aggressive, fast-growing, and therapeutically challenging brain tumors. The difficulty in managing GBM stems from its genetic instability and the intricately complex tumor microenvironment (TME). Within the TME, intricate interactions between neoplastic cells and signaling mediators drive tumor progression. Despite advances in current treatments, obstacles such as the blood-brain barrier (BBB) and pronounced inter- and intratumoral heterogeneity continue to hinder therapeutic success. Consequently, research efforts have increasingly focused on immunotherapeutic strategies that combine immune checkpoint inhibitors (ICIs) with standard-of-care (SOC) treatments or other immune-remodeling modalities, which seek to reprogram the tumor landscape and restore robust, durable anti-tumor responses. In this context, chemoradiation and oncolytic viruses induce immunogenic cell death and activate innate immunity, creating opportunities for checkpoint inhibitors to amplify T-cell responses. Complementing these strategies, engineered CAR-T cells and myeloid-targeting agents address tumor antigen loss and macrophage-mediated suppression of the immune response. Together, by targeting these complementary resistance mechanisms, combination regimens hold the potential to transform the immunologically 'cold' GBM TME into an inflamed and treatment-responsive state. Collectively, these combinatorial approaches converge to remodel the GBM microenvironment, enhancing dendritic cell (DC) activation, promoting T-cell infiltration, and thereby promoting durable anti-tumor immunity, as well as extending survival. This review provides a comprehensive analysis of the TME's role in GBM progression, highlighting the latest immunotherapeutic advances designed to address TME-related obstacles and enhance therapeutic efficacy and patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor MicroenvironmentImmunotherapyBrain NeoplasmsHumansAnimalsImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

GMBImmune evasionImmune modulationImmunotherapyTME

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • College of Biological Sciences and Biotechnology, Beijing Forestry University, Haidian, Beijing 100083, China; Faculty of Forestry, The University of British Columbia, Vancouver BC V6T 1Z4, Canada.
  • Medical Research Institute, Southwest University, Chongqing 400715, China.
  • Medical Research Institute, Southwest University, Chongqing 400715, China; Jinfeng Laboratory, Chongqing 401329, China. Electronic address: usman20236074@swu.edu.cn.
  • Department of Neurosurgery, National Clinical Research Center for Children and Adolescents' Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child…

Förderung

  • Chongqing Municipal Health Commission

Zitieren

APA

Li, J., Moqbel, A. Q., Wang, Y., Zhao, E., Ghani, M. U., & Liang, P. (2026). Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy. Biochemical Pharmacology, 246, 117724. https://doi.org/10.1016/j.bcp.2026.117724

Vancouver

Li J, Moqbel AQ, Wang Y, Zhao E, Ghani MU, Liang P. Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy. Biochemical Pharmacology. 2026;246:117724. doi:10.1016/j.bcp.2026.117724

BibTeX
@article{Li2026,
  author = {Li, Jia and Moqbel, Abdulkareem Qasem and Wang, Yongzhao and Zhao, Erhu and Ghani, Muhammad Usman and Liang, Ping},
  title = {Unraveling the glioblastoma (GBM) tumor microenvironment: future perspective on targeted immunotherapy},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {246},
  pages = {117724},
  doi = {10.1016/j.bcp.2026.117724}
}
Kostenlos starten →